Megan C Roberts1,2, Lisa P Spees2,3, Andrew N Freedman4, William M P Klein4, Irene Prabhu Das5, Eboneé N Butler6, Janet S de Moor4. 1. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC. 2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. 3. Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC. 4. Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD. 5. Office of the Director, National Institutes of Health, Bethesda, MD. 6. Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD.
Abstract
This study examines oncologist-reported reasons for not using multimarker tumor panel testing and the association between these reasons and oncologist-level, facility-level, and patient-mix characteristics. METHODS: We used data collected from a nationally representative sample (N = 1,281) of medical oncologists participating in the National Cancer Institute's National Survey of Precision Medicine in Cancer Treatment. RESULTS: In addition to testing not being seen as relevant (87%) and no evidence of test utility (77%), the most frequently reported reasons for not ordering a multimarker tumor panel test was difficulty in obtaining sufficient tissue (57%) and using individual gene tests (72%). These reasons were more likely to be reported by oncologists practicing in rural clinics and less likely to be reported by oncologists with an academic affiliation or with access to genetic services such as on-site genetic counselors and internal genetic testing policies. CONCLUSION: Modifiable, organizational factors were associated with ordering multimarker tumor panels. Receipt of genomics training and organizational policies related to the use of genomics were associated with lower reporting of barriers to ordering multimarker tumor panels, pointing to potential targets for future studies aimed at increasing appropriate multimarker tumor panel testing in cancer treatment management.
This study examines oncologist-reported reasons for not using multimarker tumor panel testing and the association between these reasons and oncologist-level, facility-level, and patient-mix characteristics. METHODS: We used data collected from a nationally representative sample (N = 1,281) of medical oncologists participating in the National Cancer Institute's National Survey of Precision Medicine in Cancer Treatment. RESULTS: In addition to testing not being seen as relevant (87%) and no evidence of test utility (77%), the most frequently reported reasons for not ordering a multimarker tumor panel test was difficulty in obtaining sufficient tissue (57%) and using individual gene tests (72%). These reasons were more likely to be reported by oncologists practicing in rural clinics and less likely to be reported by oncologists with an academic affiliation or with access to genetic services such as on-site genetic counselors and internal genetic testing policies. CONCLUSION: Modifiable, organizational factors were associated with ordering multimarker tumor panels. Receipt of genomics training and organizational policies related to the use of genomics were associated with lower reporting of barriers to ordering multimarker tumor panels, pointing to potential targets for future studies aimed at increasing appropriate multimarker tumor panel testing in cancer treatment management.
Authors: Jordan Baye; Aissa Aifaoui; Russell A Wilke; Roxana A Lupu; John Savageau; Britni Gapp; Amanda Massmann; Deidre Hahn; Catherine Hajek; April Schultz Journal: Pharmacogenomics Date: 2019-08 Impact factor: 2.533
Authors: Stephanie A Cohen; Angela Bradbury; Vida Henderson; Kent Hoskins; Erica Bednar; Banu K Arun Journal: Am Soc Clin Oncol Educ Book Date: 2019-05-17
Authors: Laura J Damschroder; David C Aron; Rosalind E Keith; Susan R Kirsh; Jeffery A Alexander; Julie C Lowery Journal: Implement Sci Date: 2009-08-07 Impact factor: 7.327
Authors: Shruti Rao; Beth Pitel; Alex H Wagner; Simina M Boca; Matthew McCoy; Ian King; Samir Gupta; Ben Ho Park; Jeremy L Warner; James Chen; Peter K Rogan; Debyani Chakravarty; Malachi Griffith; Obi L Griffith; Subha Madhavan Journal: JCO Clin Cancer Inform Date: 2020-07
Authors: May T Cho; Sepideh Gholami; Dorina Gui; Sooraj L Tejaswi; Ghaneh Fananapazir; Nadine Abi-Jaoudeh; Zeljka Jutric; Jason B Samarasena; Xiaodong Li; Jennifer B Valerin; Jacob Mercer; Farshid Dayyani Journal: Cancers (Basel) Date: 2022-01-13 Impact factor: 6.639